BCM
ROIV icon

Bayesian Capital Management’s Roivant Sciences ROIV Stock Holding History

Bayesian Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-51,000
Closed -$515K – 823
2025
Q1 		$515K Buy
+51,000
New +$552K 0.09% 287
2024
Q4 		– Sell
-48,800
Closed -$563K – 947
2024
Q3 		$563K Buy
+48,800
New +$556K 0.07% 350
2023
Q3 		– Sell
-26,376
Closed -$266K – 945
2023
Q2 		$266K Buy
+26,376
New +$236K 0.03% 570
2022
Q4 		– Sell
-17,525
Closed -$56K – 998
2022
Q3 		$56K Buy
+17,525
New +$67.9K 0.01% 625

Other funds holding ROIV

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Bayesian Capital Management's ROIV Position: Q2 2025 in Review

Bayesian Capital Management sold out of Roivant Sciences (ROIV) in Q2 2025, closing a stake of 51,000 shares — an estimated $515K sold.

Bayesian Capital Management first reported a position in ROIV in Q3 2022 and held it in 4 quarters. The position peaked at $563K in Q3 2024. 337 funds tracked by Wall St. Rank hold ROIV as of Q2 2025.

  • Bayesian Capital Management reported no remaining Roivant Sciences position as of Q2 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 51,000 Roivant Sciences shares in Q2 2025, an estimated $515K.
  • Bayesian Capital Management first reported a position in Roivant Sciences in Q3 2022 and held it in 4 quarters.
  • Bayesian Capital Management's Roivant Sciences position peaked at $563K in Q3 2024.
  • 337 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2025.

Based on Bayesian Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.